NR 565 Week 5 Empagliflozin Drug Therapy Paper Example

Adding Empagliflozin to Metformin in Type 2 Diabetes With Albuminuria: A Prescribing Decision, Its Monitoring Plan and Its Teaching Points

[Author Name]

College of Nursing, Chamberlain University

NR 565 Advanced Pharmacology Fundamentals

Week 5 Assignment

[Faculty Name]

August 11, 2026

Composite patient, written as a model document. Nothing here is prescribing guidance for any reader or any real person.

The Patient and the Therapeutic Goal

The patient is a 58-year-old woman with type 2 diabetes of nine years' duration, seen in a primary care clinic for routine follow-up. Her glycated hemoglobin is 8.6 percent, up from 7.8 percent twelve months ago, on metformin extended release 1,000 mg twice daily, which she takes reliably. Her estimated glomerular filtration rate is 52 mL/min/1.73 m2, down from 61 two years ago, and her urine albumin-to-creatinine ratio is 340 mg/g on two separate specimens three months apart. Blood pressure is 138/84 mm Hg on lisinopril 20 mg daily, body mass index is 32.4, and potassium is 4.4 mmol/L. She has never had ketoacidosis, a genital fungal infection or a hypoglycemic event.

Three goals govern the decision, and they are not equally weighted. The first is slowing kidney disease: an albumin-to-creatinine ratio above 300 mg/g with a falling filtration rate is the dominant prognostic feature in this record, and it outranks the glycated hemoglobin number by itself. The second is bringing that value toward an individualized target near 7 percent without introducing hypoglycemia, since she drives for work and lives alone. The third is avoiding further weight gain. Success at three months means a glycated hemoglobin falling toward 7.5 percent with no hypoglycemia; success at six months means an albumin-to-creatinine ratio measurably lower than 340 mg/g and a filtration rate that has stabilized after any early dip.

Defending the Choice: Empagliflozin 10 mg Daily, Added to Metformin

Empagliflozin blocks sodium-glucose cotransporter 2 in the proximal convoluted tubule, where roughly 90 percent of filtered glucose is normally reabsorbed. Blockade lowers the renal threshold for glucose, produces deliberate glycosuria of about 60 to 80 g per day, and reduces plasma glucose by a route that does not require insulin secretion, so the agent carries little intrinsic hypoglycemia risk. The accompanying natriuresis and osmotic diuresis lower systolic pressure by roughly 3 to 5 mm Hg and produce modest weight loss of 2 to 3 kg, both of which serve this patient's secondary goals. Expected glycated hemoglobin reduction is roughly 0.5 to 0.8 percentage points at her filtration rate, which is smaller than a sulfonylurea would deliver in the first months.

The kidney argument is what settles the choice. Increased sodium delivery to the macula densa restores tubuloglomerular feedback, constricts the afferent arteriole and lowers intraglomerular pressure, which is the hemodynamic reason this class slows albuminuria progression rather than merely tracking glucose. Cardiovascular and kidney outcome evidence for the class, beginning with the empagliflozin cardiovascular outcome trial, supports reduced cardiovascular death and reduced progression of kidney disease in patients who resemble this one, and current diabetes and kidney guideline statements place this class alongside metformin for people with type 2 diabetes and albuminuric chronic kidney disease. At a filtration rate of 52 mL/min/1.73 m2 she sits well above the thresholds in current labeling for starting the drug.

Two alternatives were considered and set aside for stated reasons. Glipizide would lower the glycated hemoglobin faster and cost less, but it works by forcing insulin secretion, which brings hypoglycemia risk to a woman who drives for work and lives alone, adds weight, offers no kidney or cardiovascular protection, and loses effect as beta cell function declines. Sitagliptin is well tolerated and weight neutral, but its glycemic effect is modest, it requires dose reduction as filtration falls, and it does not slow albuminuria. A glucagon-like peptide-1 receptor agonist was a genuine competitor and would have been the stronger choice had weight reduction been the leading goal, but it means an injection, higher out-of-pocket cost and gastrointestinal side effects that this patient asked to avoid.

Monitoring: Baseline Values, Intervals and Thresholds

Baseline values are already on file and are the comparison the plan depends on: filtration rate 52 mL/min/1.73 m2, albumin-to-creatinine ratio 340 mg/g, potassium 4.4 mmol/L, glycated hemoglobin 8.6 percent, weight 87 kg, blood pressure 138/84 mm Hg. A basic metabolic panel is repeated two to four weeks after the first dose. A filtration rate dip of roughly 3 to 5 mL/min/1.73 m2 at that visit is expected, is hemodynamic rather than injurious, and reverses on withdrawal; it is not a reason to stop the drug. A fall greater than 30 percent from baseline, a rise in potassium above 5.5 mmol/L, or symptomatic orthostatic change would prompt review of the whole regimen rather than of one agent.

Longer intervals carry the outcome measures. The glycated hemoglobin is repeated at three months against the 7.5 percent interim goal, and the albumin-to-creatinine ratio at three to six months, since falling albuminuria is the signal that the kidney benefit is being realized in this patient rather than in a trial population. Weight and blood pressure are recorded at every visit, because both are expected to fall slightly and an unexpected rise argues for reassessing adherence. Between visits the plan names what she reports and when: genital itching or discharge, dysuria, lightheadedness on standing, and any illness with vomiting or reduced intake. Blood ketone testing is arranged for use during illness with persistent nausea or abdominal pain.

Interactions, Cautions and Patient Teaching

Interaction review starts with her current list. Lisinopril and empagliflozin both lower blood pressure and both act on renal hemodynamics, so the combination is intended but calls for the orthostatic check above; the pairing does not raise potassium, and the sodium loss tends to offset the potassium retention the angiotensin converting enzyme inhibitor produces. Metformin has no pharmacokinetic interaction with this agent and continues unchanged. If a loop or thiazide diuretic were added later, additive volume depletion would become the leading hazard. Insulin or a sulfonylurea added to the regimen would carry real hypoglycemia risk and would need a dose reduction at the time it was started. Rifampin and other uridine glucuronosyltransferase inducers lower empagliflozin exposure.

Cautions and stopping rules belong in the record before the first dose. The drug is not appropriate in type 1 diabetes or after prior ketoacidosis, and it is stopped in pregnancy and while breastfeeding. Recurrent genital mycotic infection and prior necrotizing fasciitis of the perineum are cautions rather than paperwork; regulators have published safety communications on both ketoacidosis at near-normal glucose values and on that perineal infection. The drug is withheld during prolonged fasting, during acute illness with poor oral intake, and for several days before planned surgery, since these are the settings in which euglycemic ketoacidosis has been reported. Volume-depleted or acutely unwell patients are corrected before the drug is resumed.

Teaching was delivered in plain language and returned by teach-back. She takes the tablet each morning, with or without food, and continues metformin unchanged. Glucose will appear in her urine because that is how the drug works, so urine glucose strips are no longer meaningful for her and home fingerstick or sensor readings are used instead. She drinks to thirst and does not restrict fluids. She holds the drug and calls the clinic if she cannot keep food or fluids down for more than a day, if she is fasting for a procedure, or if she has nausea with abdominal pain and deep rapid breathing even when her glucose reads normal. She reports genital itching, discharge, or pain, swelling or redness between the genitals and the rectum with fever the same day.

References

American Diabetes Association Professional Practice Committee. (2025). Standards of care in diabetes-2025. Diabetes Care, 48(Suppl. 1). https://professional.diabetes.org/standards-of-care

Burchum, J. R., & Rosenthal, L. D. (2022). Lehne's pharmacotherapeutics for advanced practice nurses and physician assistants (3rd ed.). Elsevier.

Centers for Disease Control and Prevention. (2024). National diabetes statistics report. U.S. Department of Health and Human Services. https://www.cdc.gov/diabetes/

Kidney Disease: Improving Global Outcomes (KDIGO) Diabetes Work Group. (2022). KDIGO 2022 clinical practice guideline for diabetes management in chronic kidney disease. Kidney International, 102(5S), S1-S127. https://kdigo.org/guidelines/diabetes-ckd/

U.S. Food and Drug Administration. (2015). FDA drug safety communication: FDA warns that SGLT2 inhibitors for diabetes may result in a serious condition of too much acid in the blood. https://www.fda.gov/drugs/drug-safety-and-availability

Zinman, B., Wanner, C., Lachin, J. M., Fitchett, D., Bluhmki, E., Hantel, S., Mattheus, M., Devins, T., Johansen, O. E., Woerle, H. J., Broedl, U. C., & Inzucchi, S. E. (2015). Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. The New England Journal of Medicine, 373(22), 2117-2128. https://doi.org/10.1056/NEJMoa1504720